COVID-19

June 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

The FDA approved ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with COVID-19.

ACOG’s 2026 maternal immunization schedule outlines vaccine recommendations before, during, and after pregnancy, including influenza, COVID-19, Tdap, and RSV vaccination.

In a phase 3 trial, ensitrelvir reduced symptomatic COVID-19 after household exposure when started within 72 hours.

Recent studies in children and adults associate long COVID with worsened academic performance, attention difficulties, subjective cognitive impairment, and persistent neurologic and psychiatric symptoms. ...

New reports detail the spread of SARS-CoV-2 variant BA.3.2, Long COVID disability burden, sarbecovirus cross-immunity, and how stacked outpatient risk factors shape severe COVID-19 outcomes.

In a population-based Ontario analysis, COVID-19 vaccination was not associated with increased sudden death risk in healthy people aged 12 to 50.

New reports link SARS-CoV-2 and RSV to persistent cardiopulmonary risk and describe distinct postviral lung and brain changes in a mouse model.

This roundup explores updated 2024-2025 COVID-19 vaccine effectiveness data, an FDA-cleared 4-pathogen home test, and new evidence on metformin for long COVID risk.

A large multinational cohort study evaluated whether COVID-19 vaccination during pregnancy reduces the risk of preeclampsia, a major hypertensive complication associated with SARS-CoV-2 infection.